A comprehensive view of Generics / Biosimilars. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Logistic & Supply Chain Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Bristol Myers, Merck, and AbbVie prepare for key patent expirations this decade by focusing on patent extension strategies, developing new drugs, and acquiring smaller biotech startups; tactics are aimed at preventing profit loss from generic competition
Published: May 08, 2024 by Quartz
Leti Group decreases use of paper by printing QR codes on boxes of its Genven generics for information of interest to doctors, patients, pharmacists, health guilds; pharmacological information of the medicine can be obtained by scanning the code
Published: May 06, 2024 by CE Noticias Financieras (Latin America)
Sandoz resolves patent disputes with Amgen, clearing the way for the launch of its FDA-approved biosimilars, Jubbonti and Wyost, in the US by May 2025; the biosimilars are interchangeable with reference medicines Prolia and Xgeva
Published: May 06, 2024 by Contify Life Science News
Novo Nordisk denies FTC allegations of filing 'junk' patents to prevent competition and elevate prices for its diabetes drug, Ozempic; the company affirms their disputed patents were all approved by the US Patent Office and followed FDA regulations
Published: May 02, 2024 by Quartz
Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
Published: May 01, 2024 by BioPharma Dive

Ask us about our Logistic & Supply Chain market view

Trending Chart

Interactive chart with headline count